MaaT013 – Steroid-Refractory Acute Graft-Versus-Host Disease (SRaGvHD) program – enema
|› Evaluation of Complete Response (CR) or Very Good Partial Response (VGPR) of Steroid Refractory, Gastrointestinal, Acute Graft-Versus-Host Disease (SRaGvHD) treated with MaaT013 (pooled donors)||› First Patient In (FPI): august 2018|
› Positive DSMB 01/04 (5Pts.) Feb 01, 2019 –> Study can continue without ammendments
|Efficacy of Enema based on autologous approach in:|
› Dysbiosis correction
› Eradication of multi-drug resistant bacteria in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR MDS) undergoing chemotherapy and antibiotherapy
|› Intermediary results presented during the ASH congress in 2017|
› 2 positive DSMB (Data Safety Monitoring Board)
› 25 treated patients
› End of one year completed
- Excellent safety profile with 84% survival after one year
- 90% reconstruction of the microbiome (Simpson diversity index; p=0.0001).
- Reduction of 43% of genes coding for anti-microbial resistance
* AML: Acute Myeloid Leukemia
* MDS: MyeloDysplastic Syndromes
MaaT 033 – Oral Form – improvement of overall survival in AML patients
› Optimal dose
|› In Preparation|
What are Hematological Malignancies?
For example, there are 4 major types of leukemia:
- Acute Lymphocytic leukemia
- Chronic Lymphocytic leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
What is the worldwide estimated incidence and mortality (2012) ?
|Incidence (% all cancers)||Mortality (% all cancers)|
|Leukemia||351 965 (2.5%)||265 471 (3.2%)|
|Hodgkin’s Lymphoma||65 950 (0.5%)||25 469 (0.3%)|
|Non-Hodgkin’s Lymphoma||385 741 (2.7%)||199 670 (2.4%)|
|Multiple Myeloma||114 251 (0.8%)||80 019 (1.0%)|
Source – globocan.iarc.fr / 2012
Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.
We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.